邁克生物(300463.SZ):郭雷及王傳英擬減持公司股份
格隆匯11月8日丨邁克生物(300463.SZ)公佈,公司於近日收到實際控制人之一郭雷出具的《關於計劃減持公司股份的告知函》,計劃自2019年11月28日至2020年02月26日(窗口期不減持),通過大宗交易方式減持不超過約1115.11萬股公司股份,即不超過公司當前總股本(扣除回購專用賬户持有股份數量後)的2%;
收到持股5%以上股東王傳英出具的《關於計劃減持公司股份告知函》,計劃自公告披露之日起15個交易日後的90個自然日內(窗口期不減持),通過集中競價方式減持不超過約557.55萬股公司股份,即不超過公司當前總股本(扣除回購專用賬户持有股份數量後)的1%,自公告披露之日起3個交易日後的90個自然日內(窗口期不減持),通過大宗交易方式減持不超過約557.55萬股公司股份,即不超過公司當前總股本(扣除回購專用賬户持有股份數量後)的1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.